上皮性卵巢癌中AIB1蛋白的表达及其临床意义

doi:10.3877/cma.j.issn.1673-5250.2007.01.113

目的

研究AIB1蛋白在卵巢癌细胞株SKOV3，上皮性卵巢癌组织中的表达，探讨其在卵巢肿瘤发生发展中的作用及临床意义。

方法

采用免疫组化SP法检测卵巢癌细胞株SKOV3。检测本组20例正常卵巢组织、30例卵巢良性肿瘤及74例上皮性卵巢癌中AIB1蛋白的表达情况，并与临床病理特征相比较。

结果

卵巢癌细胞株SKOV3中，AIB1蛋白呈高表达状态。卵巢癌组织中，AIB1蛋白的阳性表达率明显高于正常卵巢和卵巢良性肿瘤。随着肿瘤分化程度的逐渐降低，AIB1蛋白的阳性表达率呈不断升高的趋势(P= 0.018)。随着肿瘤临床分期逐渐升高，AIB1的表达亦明显升高(P=0. 006)。

结论

AIB1蛋白的表达与上皮性卵巢癌的发生发展、细胞分化程度、临床分期密切相关。

关键词: 卵巢肿瘤, AIB1蛋白, 免疫组化

Objective

To investigate the expression of AIBl (amplified in breast cancer 1) protein in ovarian cancer cell line SKOV3 and epithelial ovarian cancer ; to analyze its role and clinical significance in carcinogenesis and development of ovarian cancer.

Methods

We examined the AIBl expression levels and relation to clinico-pathological features in ovarian cancer cell line SKOV3,20 normal ovarian tissues,30benign ovarian tumors and 74 epithelial ovarian cancers by immunohistochemical method SP.

Results

High levels of AIBl expression were observed in ovarian cancer cell line SKOV3. The positive expressions of AIBl in epithelial ovarian cancers were significantly higher than those in normal tissues and benign ovarian tumors. It showed the tendency that the expression of AIBl increased with the decrease of histological differentiation (P= 0. 018) and progress of clinical stages (P= 0. 006).

Conclusion

The overexpression of AIBl is obviously related to the carcinogenesis and development of epithelial ovarian cancer.

Key words: ovarian cancer, AIBl protein, immunohistochemical

图1　卵巢癌细胞株SKOV3-AIB1表达(免疫组化×200)

图2　卵巢浆液性上皮性腺癌AIB1表达(免疫组化×100)

	1　Kuang SQ, Liao L，Wang S, et al. Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis. Cancer Res,2005,65(17):7993-8002.
	2　Minna K，Tikkanen，Damien J, et al. Endogenously expressed estrogen receptor and coactivator AIBl interact in MCF-7 human breast cancer cells. Proc Natl Acad Sci USA，2000，97(23)：12536-12540.
	3　Ralf TH，Bassem R，Haddad SEK，et al. Overexpression of the nuclear receptor coactivator AIBl (SRC-3) during progression of pancreatic adenocarcinoma. Clin Cancer Res,2004,10：6134-6142.
	4　Xu J, Liao L, Ning G,et al. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIBl/ACTR/TRAM-l) is required for normal growth, puberty, female reproductive function, and mammarygland development. Proc Natl Acad Sci USA,2000，97(12)：6379-6384.
	5　Anzick SL, Kononen J，Walker RL，et al. AIBl，a steroid receptorcoactivator amplified in breast and ovarian cancer. Science，1997，277:965-968.
	6　David O. Azorsa P, Meltzer S. Production and characterization of monoclonal antibodies to the steroid receptor coactivator AIBl. Hybridoma, 1999, (18)：281-287.
	7　Liao L, Kuang SQ, Yuan Y, et al. Molecular structure and biological function of the cancer-amplified nuclear receptor coactivator SRC-3/AIB1. J Steroid Biochem Mol Biol, 2002,83 (1-5) :3-14.
	8　Hudelist G，Czerwenka K，Kubista E, et al. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue：AIBl is a carcinoma-specific co-activator. Breast Cancer Res Treat, 2003,78(2)：193-204.
	9　Sarraf S，Tejada R, Abawi M, et al. The human ovarianteratocarcinoma cell line PA-1 demonstrates a single translocation：Analysis with fluorescence in situ hybridization, spectral karyotyping, and bacterial artificial chromosome microarray. Cancer Genet Cytogenet, 2005，161 (1): 63-69.
	10　Anzick SL，Azorsa DO, Simons SS，et al. Phenotypic alterationsin breast cancer cells overexpressing the nuclear receptor co¬activator AIBl. BMC Cancer,2003, 3：22.
	11　Font de Mora J，Brown M. AIBl is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol,2000,20(14)：5041-5047.
	12　Kuang SQ, Liao L, Zhang H, et al. AIBl/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res,2004,64：1875-1885.
	13　Minna M. Tanner S，Grenman AK, et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res,2000, 6:1833-1839.

[1]	卢菊, 赵胜, 范建华, 高艳多. 探讨IOTA、GI-RADS及O-RADS在附件肿瘤良恶性鉴别诊断中的价值[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(05): 484-490.
[2]	何欣林, 阎昊铮, 赵亦非, 江彩霞, 李征宇. 新辅助化疗联合间歇性肿瘤细胞减灭术对上皮性卵巢癌患者预后及血清学与影像学指标对患者预后的预测价值[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(01): 47-57.
[3]	林昌盛, 战军, 肖雪. 上皮性卵巢癌患者诊疗中基因检测及分子靶向药物治疗[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 505-510.
[4]	刘星辰, 刘娟, 魏宝宝, 刘洁, 刘辉. XIAP与XAF1异常表达与卵巢癌的相关性分析[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 419-427.
[5]	陈荟竹, 郭应坤, 汪昕蓉, 宁刚, 陈锡建. 上皮性卵巢癌"二元论模型"的分子生物学研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 394-402.
[6]	胡宁宁, 赵延荣, 王栋, 王胜亮, 郭源. FMNL3与肝细胞癌肝移植受者预后的相关性研究[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 283-288.
[7]	司钦亮, 毕世龙, 焦慧骁, 李世照, 陈哲禹, 武玉东. 精索去分化脂肪肉瘤两例并文献复习[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 585-590.
[8]	罗桓, 王智园, 杨莹, 张映林, 黎贵芸, 李方方, 边莉. 胸壁黏液炎性纤维母细胞肉瘤一例[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(01): 128-131.
[9]	刘庭秀, 刘新敏, 刘莹, 隋娟, 武宇, 赵瑜敬, 毕红, 孙雪梅, 范秀华. 腹壁整形术后腹腔镜新脐入路治疗卵巢肿物的安全性探讨[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(03): 189-192.
[10]	牛文博, 吴凤鹏, 刘月平, 周超熙, 张娟, 胡旭华, 李保坤, 王贵英. 新辅助放化疗对局部进展期直肠癌疗效及肿瘤免疫微环境变化的研究[J/OL]. 中华临床医师杂志(电子版), 2023, 17(05): 519-523.
[11]	汪泉, 周英妹, 何颖. p27、cyclin-E在子宫内膜异位症中的表达及其临床意义[J/OL]. 中华临床医师杂志(电子版), 2022, 16(06): 546-552.
[12]	张允耀, 王静, 范爱娟, 牟海萍. 超声诊断卵巢交界性肿瘤临床价值的荟萃分析[J/OL]. 中华诊断学电子杂志, 2024, 12(02): 85-89.
[13]	刘育昕, 王子晗, 张艺馨, 栾永婕, 孟凯. 肾母细胞瘤基因1在卵巢疾病发病机制中的研究进展[J/OL]. 中华诊断学电子杂志, 2023, 11(03): 178-183.
[14]	王可珺, 李吉镇, 马标, 续慧超, 谌红珊, 刘雷. 肌酐/胱抑素C对晚期上皮性卵巢癌术后并发症的预测价值[J/OL]. 中华诊断学电子杂志, 2023, 11(01): 49-55.
[15]	卢晓云, 俞姝含, 吴泽宇, 张其德, 吴沛瑶. CCR2、CCL2、Foxp3在结肠癌组织中的表达及其临床意义[J/OL]. 中华胃肠内镜电子杂志, 2023, 10(01): 52-56.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

The expression and clinical significance of AIB1 protein in ovarian cancers

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

The expression and clinical significance of AIB1 protein in ovarian cancers